REGN - Alnylam Pharma is said to be a potential target for Novartis - Bloomberg

Alnylam Pharmaceuticals (NASDAQ:ALNY) may be a potential target for Novartis as investor push for the drugmaker to make an acquisition. Alnylam, with a market cap of more than $20B could be a possible acquisition candidate, according to a Bloomberg report, which cited people familiar. Novartis declined to comment to Bloomberg on potential acquisitions. Earlier this month, Intellia Therapeutics, Alnylam seen as potential Regeneron (NASDAQ:REGN) targets, analyst says.  Benchmark analyst Aydin Huseynov wrote that ALNY would likely be worth more than $30B in an acquisition.

For further details see:

Alnylam Pharma is said to be a potential target for Novartis - Bloomberg